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Summary A syngeneic, androgen-sensitive Dunning R3327 rat prostatic adenocarcinoma was transplanted bilaterally in the flanks of male
Copenhagen Fisher rats. Approximately 3 months after implantation, when the tumours had a median volume of 150 mm3, one group of rats
was treated with histamine alone (4 mg kg-1 subcutaneously on weekdays), another group with human recombinant interleukin 2 (IL-2) alone
(425 IU kg-' continuous infusion) and a third group with both histamine and IL-2 during 6 weeks. Tumours on one flank were irradiated (6 Gy
once daily for 3 days to a total dose of 18 Gy) beginning 1 week after the onset of treatment with histamine and / or IL-2. The contralateral
tumour served as the intra-animal control. The tumour volumes were determined weekly. The growth curves showed that all three drug
treatments were effective in delaying growth, but when used individually did not cause tumour shrinkage. Radiation was the most effective
single agent, but when used alone the shrinkage did not occur until 2 weeks after irradiation. When combined with the drugs, more rapid and
extensive growth delay and/or shrinkage was seen. The growth curves showed clear differences between the different treatments. The
combination of the three agents was the most effective of all. The most striking difference between radiation alone and radiation plus
biotherapy was the time at which a tumour response was detectable. Thus, active biotherapy alone and especially in a combination with
histamine and radiotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.
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The pivotal role ofthe cytokine interleukin 2 (IL-2) in the immune
system has promoted trials of IL-2 in patients with solid cancers
such as melanoma and renal cell carcinoma (Atzpodien et al,
1995). IL-2 effectively stimulates the anti-tumour activity of
natural killer (NK) cells and othercytotoxic cells in the majority of
treated patients (Caligiuri et al, 1993), but the effects on tumour
burden and on the survival of patients have, as yet, been disap-
pointing. The detailed mechanisms that explain the poor clinical
outcome are not known.
In the inflammatory tissue adjacent to tumours, the predominant
leucocytes are usually phagocytes such as monocytes and granulo-
cytes. Recent studies suggest that NK cells are only weakly acti-
vated by IL-2 in the presence of phagocytes in vitro, presumably
because of the production of an inhibitory signal from the phago-
cytes (Hellstrand et al, 1994a). Histamine, a biogenic amine,
counteracts this phagocyte-derived suppressive signal. Thereby,
histamine may synergize with IL-2 to induce NK cell-mediated
killing ofavariety ofcultured tumourcells in vitro (Hellstrand and
Hermodsson, 1990; Hellstrand et al, 1994b). Treatment of mice
with histamine also enhances the IL-2-induced activation of NK
cells in vivo (Asea et al, 1996) and addition of histamine to
conventional IL-2 therapy has shown initial promise in patients
with metastatic melanoma (Hellstrand et al, 1994a) and acute
myelogenous leukaemia (Brune and Hellstrand, 1996).
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It is also of interest to observe that radiation reduces the
T-helper cell function, but not that of macrophages or NK cells
(Reizenstein et al, 1985).
The Dunning R3327 rat prostatic adenocarcinoma arose
spontaneously in a male Copenhagen rat and has been carried
subcutaneously as several distinct tumour cell lines. It is well
differentiated, considered to be a non-immunogenic, low-grade
and hormone-sensitive prostate adenocarcinoma and a suitable
model for established human prostatic carcinoma (Smolev et al,
1977). The tumours have previously been shown to be radiosen-
sitive (Thorndyke et al, 1985). Previous studies have also shown
that IL-2 significantly delays tumour growth in this in vivo model,
even when treatment is initiated several months after tumour
implantation (Henriksson et al, 1992; Moody et al, 1994).
In the present study, we have investigated whether treatment
with histamine alone, IL-2 alone or IL-2 in a combination with
histamine influences the growth oftumours receiving drugs alone
or concomitant with radiation treatment of Dunning R3327
prostatic adenocarcinoma in rats. The growth pattern during treat-
ment, the volume and the appearance of the tumours have been
evaluated both macroscopically and microscopically at sacrifice.
MATERIALS AND METHODS
Animals
A 1-mm3 cube of prostatic adenocarcinoma tissue (Dunning
R3327) was implanted bilaterally into each flank of 10-week-old,
male offspring ofCopenhagen X Fisher Fl rats at the Department
of Physiology, University of Umea, Sweden. The tumours were
originally obtained from Dr NH Altman (Organ System Program
of the National Cancer Institute, USA). The animals were housed
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in a controlled environment (12 h light/12 h dark) with pellets and
water freely available. Approximately 3 months after implanta-
tion, when the weight ofthe rats had reached 460 g (430-480) and
the tumours had a median volume of 150 mm3 (122-340), eight
rats were chosen at random for IL-2 treatment, eight rats for hista-
mine treatment, eight rats fortreatment with acombination ofIL-2
and histamine treatment, and six rats were used as controls.
IL-2 and histamine administration
IL-2 was continuously delivered as a subcutaneous infusion using
an Alzet micro-osmotic pump (model 2002) implanted on the neck
for 6 weeks oftreatment (Alza, Palo Alto, CA, USA). This model
makes itpossible todeliverasteadyconcentrationofdrug(0.5 p1 h-1
for 14 days). The pumps were filled with IL-2 solution in a
concentration of 1.8 x 106 IU in 200gl, which delivers a daily
dose of 425 IU kg-'. Every 2 weeks the pumps were replaced,
providing fresh solution.
Histamine was administrated subcutaneously five times a week
(Monday to Friday) in a dose of4 mg kg-', starting 2 days after the
implantation of IL-2 pumps and delivered until the termination of
the experiment (6 weeks).
Radiation therapy procedures
The right side of each tumour-bearing rat was irradiated 7 days
after the implantation ofIL-2 pumps and the contralateral tumours
were used as the intra-animal controls. The rats were irradiated
with a fractionated schedule. A dose of 6 Gy was given on three
consecutive days with X-rays from a medical linear accelerator
(6 MV). Focus to skin distance was 100 cm. The rats were firmly
anaesthetized using methohexital (Brietal) administrated intraperi-
toneally and fixed in a plastic net mould during each irradiation
period. During irradiation the rats were checked through a TV
camera, and if they moved the treatment was temporarily inter-
rupted to realign them. The total radiation field was 5 x 10 cm as
two rats were irradiated at the same time, and the rats were
also carefully shielded to reduce the scattered dose of radiation
to normal tissues outside the treatment field, trying to avoid
irradiating the intestine.
Tumour growth
The tumours reached treatment size approximately 3 months after
inoculation. They were measured weekly, always by the same
person, with callipers in three mutually orthogonal directions.
Tumour volumes were calculated assuming spherical geometry,
using the formula V=i/6 x D1 x D2x D3. The day ofimplantation
of IL-2 pumps was designated as day 0. Tumour response to
various treatments is shown graphically as mean tumour volume
(of the six to eight tumours per treatment group) as a function of
time after the start of treatment. The weight of the rats was also
measured weekly.
Statistical analyses
Values are expressed as means ± s.e.m unless otherwise indicated.
For comparisons between groups the Mann-Whitney U-test was
used to obtain the P-values.
RESULTS
General effects
No obvious toxicity was observed during the treatment period; in
particular, there were no signs of radiation-induced gastro-
intestinal complications. The body weight of rats 1 week before
and for 5 consecutive weeks after radiation treatment was
measured. A 7-10% weight loss was observed 1 week after
irradiation in all groups. They all recovered, except the total
combined treatment group in which the weight loss persisted
throughout the observation period.
Tumour growth
Figure 1 shows the growth curves of the groups of tumours
receiving a single therapy. The untreated Dunning R3327 tumours
show continuous growth over the 6-week period, with a volume
doubling time of 2 weeks, slowing to more than 4 weeks as the
experiment progressed. Radiation is the most effective single
agent, causing regression below its initial treatment size but with
regrowth commencing at weeks 5 and 6. Histamine alone is the
least effective treatment. IL-2 is intermediate.
Figure 2A-D shows the effect of the various combinations. If
histamine and IL-2 are combined, the end result is similar to IL-2
alone, although at early times the combination appears more effec-
tive. If IL-2 is added to 18 Gy, the net result is similar to 18 Gy
alone, even although pretreatment for 1 week with IL-2 made the
tumours smaller at the time ofirradiation. Ifhistamine is added to
18 Gy, the response is similar up to week 4, but appears more
effective at late times. The most effective treatment is the combi-
nation of all three agents (histamine, IL-2 and radiation), which
is significantly greater than the response to radiation alone at
2 weeks, but not at 6 (Table 1).
Figure 3 displays a comparison of volumes of the eight groups
of tumours at week 2 and week 6. Adjacent columns allow
comparison ofthe irradiated and unirradiated tumours on the same
rats, exposed toprecisely the same drug regimes. The drugs reduce
the volume of the tumours compared with those in an untreated
group of rats. The addition of the drugs to radiotherapy also
deceased the size, although the difference was not statistically
significant at later times (see Table 1).
At the end of the experiment, 5 weeks after irradiation, the
control tumours had grown to 3.5 times the initial volume. In the
irradiated groups none of the tumours had reached double the
initial tumour volume. In every animal the irradiated tumours were
considerably smaller than the unirradiated contralateral tumours.
Figure 4 shows the calculated time to reach 175%, 200% and
250% of the initial volume. This time was obtained from the
growth curves. The volume doubling time is 14 days in the control
group, and histamine alone increased the time to double to 23
days, IL-2 alone to 32 days, whereas IL-2 and histamine treatment
together increased the doubling time to 37 days. The volume
doubling time of the irradiated groups could not be evaluated as
none of the irradiated tumours had reached double size when the
study was finished and the animals were killed.
Tumour morphology
Figure 5 shows photomicrographs of control, untreated tumours
and those irradiated alone or with single or combination drugs.
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Figure 1 Growth curves of Dunning R3327 tumours exposed to single agents, as indicated. Drugs given continuously from day0, radiation given as 3 x 6Gy
on days 7-9. A, Control; V. histamine; 0, IL-2; A, radiation therapy
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Figure 2 Four panels to illustrate the tumour growth curves after single agents and combination of two or three agents during the treatment period. Drugs
given continuously from day 0, radiation given as 3 x 6 Gy on days 7-9. (A)V. Histamine; 0, IL-2;L, histamine + IL-2. (B)0, IL-2; A, radiation therapy;
*, IL-2 + radiation therapy. (C)V. Histamine; A, radiation therapy; V, histamine + radiation therapy. (D)Ci, Histamine + IL-2; A, radiation therapy;
*, histamine + IL-2 + radiation therapy
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Table 1 Statistical analysis of the results obtained in Figures 2 and 3 using the Mann-Whitney U-test
Agent used
Assay time Radiation IL-2 Histamine IL-2 + Histamine
Versus untreated 2 weeks n.s. P < 0.037 P < 0.053 P < 0.009
control tumours 6 weeks P< 0.015 NS NS NS
RT+IL-2 RT+Histamine RT+IL-2+Histamine
Versus radiation only 2 weeks - P < 0.021 P < 0.001 P< 0.002
6 weeks - NS NS NS
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Figure 3 Histogram to show the relative volumes of tumours (on opposite
flanks of rats) treated with drugs alone or in combination with radiotherapy at
(A) 2 weeks after initiating drug therapy and at (B) 6 weeks, i.e. at termination
of experiment. D1, Radiation therapy; *, no radiation therapy
Macroscopically at sacrifice, it was evident that histamine alone
and in combinations with the othermodalities caused alterations in
the tumour tissue with the appearance of haemorrhagic cystic
structures. This was most evident in the tumours receiving the full
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Figure 4 Delay in regrowth of tumours treated with drugs alone. Time taken
to reach different end point volumes are shown in the three sections. O,
Control; *, histamine; E, IL-2; El, histamine + IL-2
combination. The untreated tumours in rats in which the contra-
lateral tumour was irradiated can be regarded as untreated
controls for comparative morphological analysis.
Microscopically, these control tumours were composed of a
high density ofglandular structure embedded in a small amount of
stroma (Figure 5A). The irradiated tumours showed a clear alter-
ation of the morphology with a decreased amount of tumour cells
surrounded by a cell-rich stroma (Figure 5B). In irradiated
tumours treated with histamine, an even more pronounced reduc-
tion in the numberoftumourcells was found when compared with
control tumours and the contralateral, non-irradiated tumours. The
tumour stroma was rich in collagen fibres with far fewer scattered
cells (Figure 5C). In irradiated tumours treated with IL-2, a reduc-
tion in the number of tumour cells was found and the tumour
stroma consisted mainly of fibrous tissue with scattered stromal
cells (Figure4D). The majordifference in these irradiated tumours
is in the cellularity of the stroma. Irradiated tumours treated with
both IL-2 and histamine were most dramatically damaged by the
treatment. In some tumours even large areas resembling the
picture ofcoagulative necrosis were observed (Figure 5E).
DISCUSSION
This study for the first time, as far as we know, demonstrates that
IL-2, especially in combination with histamine, alters the time
scale of response to radiation. The results are in accordance with
earlier observations that a direct and specific manipulation of the
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immune system can mediate growth delay of different kinds of
established tumours in experimental models as well as in humans,
including prostatic carcinoma (Mador et al, 1982; Lahat et al,
1989; Henriksson et al, 1992).
The present results showed that the three agents given alone or
in various combinations affected both the growth rate of the
tumours during the experimental period and the morphology at
sacrifice. Each agent was effective as a single agent, in the
increasing order, histamine, IL-2 and radiation. When combined,
histamine and IL-2 were more effective than histamine and IL-2
alone, but less effective than radiation alone. However, when the
combination treatment with histamine and IL-2 was added to
Figure 5 Tumour histopathology at 5 weeks after irradiation of the tumours
treated with histamine and/or IL-2. (A) Control, not irradiated; (B) irradiated;
(C) histamine and irradiated; (D) IL-2 and irradiated; (E) histamine and IL-2
and irradiated
radiation, the tumour growth was most retarded. From the
histology, the most effective was the treatment with all three
agents together.
Previous experimental studies, also in accordance with our data,
have shown that in histamine-treated animals large and numerous
foci of haemorrhagic necroses were found (Burtin et al, 1985).
This was evident macroscopically in our study, with an increased
frequency of haemorrhagic cystic structures in all groups that
received histamine. The observation might indicate vascular
damage due to the histamine administration itself. An increased
vascular permeability at the site of tumour growth may facilitate
local entry of sensitized T cells that are activated to produce
lymphokines. These lymphokines may attract leucocytes from
the circulation with a potential anti-tumour activity such as
macrophages and NK cells (Van Loveren et al, 1985). Moreover,
activated macrophages have been reported to have cytotoxic
effects also on endothelial cells (Peri et al, 1990). The fact that
cytokines cause changes in blood pressure, vascular permeability
and other damage to both small and large blood vessels cannot be
ignored either. Decreased blood pressure may result in a decreased
blood flow in tumours (steal effect), and an increased vascular
permeability caused by both histamine and IL-2 could give rise to
an increased interstitial pressure. These factors could be involved
in decreasing and/or shutting off the blood flow in tumours
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compared with normal tissues. Subsequently, ifthe tumour cannot
get enough oxygen and nutrients, then their growth is impaired
(Denekamp, 1990).
The administration of one cytokine often triggers a cascade of
secondary cytokine releases that may contribute to or antagonize
the effect of the given agent. It is known that IL-2-activated blood
lymphocytes release a number of secondary cytokines such as
interferon-y (IFN-y), tumour necrosis factor-a (TNF-a) and
granulocyte-macrophage colony-stimulating factor. Some of these
cytokines have been reported to inhibit sex steroid or gonadotropin
secretion (Meikle et al, 1987). As the Dunning R3327 rat prostatic
adenocarcinoma is hormone sensitive, the possibility of an inhibi-
tion ofLH secretion and testosterone synthesis cannot be excluded.
However, the weight ofthe prostate itselfwas only slightly reduced
after IL-2 and/or histamine compared with what had previously
been seen after total androgen deprivation (data not shown).
The Dunning R3327 rat prostatic adenocarcinoma initially was
aspontaneously derived tumourthatwastransplanted syngeneically
to its inbred rat strain with a normal immunological status (Isaacs,
1987). It therefore serves as a suitable model to study the outcome
of radiation treatment combined with immunotherapy. With this
tumour, as with all other rodent models, the doubling time is
shorter than that of human tumours (Meyer et al, 1993).
Fractionated radiotherapy is an acceptable form of treatment of
human prostate cancer. Repopulation of tumour cells can occur
during the fractionated treatments. The combination of different
approaches such as active biotherapy with histamine and IL-2,
and/or LHRH analogues during radiation treatment may inhibit
repopulation ofthe tumour cells in addition to enhancing the effect
of radiation by adding more cytotoxicity to the tumour cells.
Although this is not evident as a contributing mechanism to retar-
dation of tumour growth in our study, this strategy might be
considered as having potential benefits and deserves further study.
In our study it is evident that following tumour volumes in
experimental studies without biopsies does not give enough infor-
mation about what is happening in the tumour. For example, in
growth terms, histamine seems to have much less effect than IL-2
on tumour growth in this study, but this hides the differences that
were detected within the tumours at post-mortem The tumours
from rats receiving histamine were often cystic and/or necrotic, so
that the actual volume of tumour cells would be much lower than
would be anticipated from the growth curves.
This experimental set-up, in which the rats are killed at the end
ofthe treatment, allows the structural and microscopic changes to
be observed, but does not permit the outcome in terms ofdelayed
regrowth after cessation of treatment to be followed. This was a
particular problem for the irradiated tumours. The reduction of
volume by the factor of about 2-3 compared with controls indi-
cates a considerable cytostatic or cytotoxic effect. The histology
indicated that most of the tumour islets have been destroyed and
most ofthe residual material is stroma. The nature ofthe stroma is
markedly different in irradiated tumours receiving concomitant
treatment with the immunostimulatory agents. Various alterations
of the stromal and epithelial compartments have also been
described in prostatic carcinoma (Dunning R3327) after hormonal
manipulation with a rapid infiltration of activated macrophages
preceding tumour cell death (Landstrom et al, 1997).
In conclusion, these data suggest that the novel combination of
histamine and IL-2 could be of interest to enhance the effects of
irradiation. In addition to enhancing the local effect on the irradi-
ated tumour, the systemic treatment could also affect the growth of
tumour outside the primary tumour. However, further studies are
needed to delineate the ultimate growth delay, the mechanisms of
action and to find the optimal schedule ofthis treatment before the
final value of this approach can be established. Taking into
account the difference in the growth rates of human and rodent
tumours, direct extrapolation and prediction of the magnitude of
any clinical benefit from such an approach must be carried out
with caution at this stage.
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